Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:DBVT NASDAQ:DTIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsDBVTDBV Technologies$18.54+0.2%$20.38$7.53▼$26.18$1.10B-0.96293,789 shs108,154 shsDTILPrecision BioSciences$7.18+4.1%$6.77$3.53▼$8.82$185.26M1.31256,189 shs176,790 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-80.12%DBVTDBV Technologies-1.28%-7.45%-13.26%-9.93%+71.39%DTILPrecision BioSciences-0.86%-15.85%-12.44%+79.22%+47.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsDBVTDBV Technologies$18.54+0.2%$20.38$7.53▼$26.18$1.10B-0.96293,789 shs108,154 shsDTILPrecision BioSciences$7.18+4.1%$6.77$3.53▼$8.82$185.26M1.31256,189 shs176,790 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-80.12%DBVTDBV Technologies-1.28%-7.45%-13.26%-9.93%+71.39%DTILPrecision BioSciences-0.86%-15.85%-12.44%+79.22%+47.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.75Reduce$0.50763.56% UpsideDBVTDBV Technologies 2.67Moderate Buy$40.25117.10% UpsideDTILPrecision BioSciences 2.50Moderate Buy$36.33406.04% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, DBVT, and ADAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026DTILPrecision BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.005/1/2026DBVTDBV Technologies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/1/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$47.00 ➝ $55.004/17/2026DTILPrecision BioSciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/27/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$45.00 ➝ $47.003/27/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.003/13/2026DTILPrecision BioSciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.09N/AN/A$0.05 per share1.16DBVTDBV TechnologiesN/AN/AN/AN/A$3.51 per shareN/ADTILPrecision BioSciences$45.07M4.11N/AN/A$2.95 per share2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%N/ADBVTDBV Technologies-$146.95M-$4.46N/AN/AN/A-2,895.37%-129.88%-88.84%7/29/2026 (Estimated)DTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)Latest DTIL, DBVT, and ADAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 million4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 million3/26/2026Q4 2025DBVTDBV Technologies-$0.1935-$1.15-$0.9565-$4.43$1.06 million$0.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29DBVTDBV TechnologiesN/A4.764.76DTILPrecision BioSciences0.2914.0214.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%DBVTDBV Technologies71.74%DTILPrecision BioSciences37.99%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%DBVTDBV Technologies1.06%DTILPrecision BioSciences2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableDBVTDBV Technologies8059.21 million58.58 millionOptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataDTIL, DBVT, and ADAP HeadlinesRecent News About These CompaniesPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual MeetingMay 14, 2026 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Precision BioSciences (DTIL)May 12, 2026 | theglobeandmail.comPrecision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2026 | zacks.comPrecision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPSMay 5, 2026 | marketbeat.comPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 5, 2026 | businesswire.comPrecision BioSciences (DTIL) Projected to Post Earnings on TuesdayMay 2, 2026 | marketbeat.comPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026April 30, 2026 | businesswire.comPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD StudyApril 29, 2026 | tmcnet.comPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingApril 28, 2026 | businesswire.comPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 24, 2026 | businesswire.comPrecision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026April 22, 2026 | pharmiweb.comPPrecision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 15, 2026 | seekingalpha.comPrecision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European CountriesApril 15, 2026 | businesswire.comShould You Buy Precision BioSciences (DTIL) After Golden Cross?April 14, 2026 | zacks.comPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | businesswire.comPrecision BioSciences, Inc. (DTIL) Shareholder/Analyst Call TranscriptMarch 17, 2026 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Precision BioSciences (DTIL)March 12, 2026 | theglobeandmail.comPrecision BioSciences: Q4 Earnings SnapshotMarch 12, 2026 | stamfordadvocate.comSPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | tmcnet.comPrecision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue EstimatesMarch 12, 2026 | zacks.comPrecision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV ProgramMarch 11, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDTIL, DBVT, and ADAP Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.DBV Technologies NASDAQ:DBVT$18.54 +0.03 (+0.16%) Closing price 04:00 PM EasternExtended Trading$18.49 -0.05 (-0.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Precision BioSciences NASDAQ:DTIL$7.18 +0.28 (+4.06%) Closing price 04:00 PM EasternExtended Trading$7.16 -0.01 (-0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
